Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
First clinical data from five planned randomized controlled trials Show favorable fusion rate compared to autograft…
Fusion rate 78%, vs 42% for autograft and 55-71% for other synthetic bone grafts First of five planned randomized contro…
Mit dem neuen Affinis Inverse Bone Grafting Instrumentarium erweitert das Medizinaltechnikunternehmen Mathys sein Portf…
With the new Affinis Inverse Bone Grafting Instruments, the medical technology company Mathys is expanding its portfolio…
The medical technology company Mathys, based in Bettlach, Switzerland, is expanding its portfolio in the field of hip re…
MagnetOs Granules and MagnetOs Putty receive TGA approval in Australia Initial launch of MagnetOs on the Australian mark…
CHF 16.0 million cash & cash equivalents, trade and other receivables as at June 30, 2020 Revenues increased to CHF 1.3…
Financial highlights CHF 13.4 million cash and cash equivalents (including trade and other receivables) at June 30, 20…
Global partner to market an advanced bone graft supplied by Kuros Agreement demonstrates interest of major orthobiologic…